Tag: State University of New York

Improving the effectiveness of an anticancer fluoropyrimidine by molecular hybridisation

Written by
Dr Kalman redesigned the anticancer drug capecitabine (Cape)to resist metabolic conversion to 5-fluorouracil and thereby prevent its associated potentially fatal toxicities.

Capecitabine (Cape) – a fluoropyrimidine used primarily in the treatment of breast and colorectal cancer – disrupts the synthesis of DNA in cancer cells following its conversion to 5-fluorouracil (FU). Since FU has been associated with several potentially fatal side effects, Dr Thomas I. Kalman at the University at Buffalo and The State University of New York has developed a […]

Read More… from Improving the effectiveness of an anticancer fluoropyrimidine by molecular hybridisation